Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Non-Current Debt (2021 - 2025)

Ascendis Pharma A's Non-Current Debt history spans 3 years, with the latest figure at $239.9 million for Q4 2023.

  • For Q4 2023, Non-Current Debt fell 51.31% year-over-year to $239.9 million; the TTM value through Dec 2023 reached $239.9 million, down 51.31%, while the annual FY2023 figure was $241.2 million, 52.61% down from the prior year.
  • Non-Current Debt for Q4 2023 was $239.9 million at Ascendis Pharma A, down from $492.7 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $492.7 million in Q4 2022 and bottomed at $112.1 million in Q4 2021.
  • The 3-year median for Non-Current Debt is $239.9 million (2023), against an average of $281.6 million.
  • The largest annual shift saw Non-Current Debt surged 339.67% in 2022 before it tumbled 51.31% in 2023.
  • A 3-year view of Non-Current Debt shows it stood at $112.1 million in 2021, then skyrocketed by 339.67% to $492.7 million in 2022, then crashed by 51.31% to $239.9 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Non-Current Debt are $239.9 million (Q4 2023), $492.7 million (Q4 2022), and $112.1 million (Q4 2021).